294 related articles for article (PubMed ID: 15008469)
21. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
Sekine M; Takami H
Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
[TBL] [Abstract][Full Text] [Related]
22. [Malignancy-associated hypercalcemia].
Oura S
Nihon Rinsho; 2003 Jun; 61(6):1006-9. PubMed ID: 12806951
[TBL] [Abstract][Full Text] [Related]
23. [Hypercalcemia in malignant diseases. Physiopathology and treatment].
Aasarød K; Lamvik J
Tidsskr Nor Laegeforen; 1989 Apr; 109(12):1293-6. PubMed ID: 2734758
[TBL] [Abstract][Full Text] [Related]
24. [Treatment for the electrolytic disorders in cancer patients].
Shibata H
Gan To Kagaku Ryoho; 2008 Dec; 35(13):2330-3. PubMed ID: 19098400
[TBL] [Abstract][Full Text] [Related]
25. [Biphosphonates in oncology].
Khosravi Shahi P; Díaz Muñoz de la Espada V
An Med Interna; 2005 Nov; 22(11):544-7. PubMed ID: 16454591
[TBL] [Abstract][Full Text] [Related]
26. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
27. Use of bisphosphonates for resistant hypercalcemia in children with acute lymphoblastic leukemia: report of two cases and review of the literature.
Andiran N; Alikaşifoğlu A; Küpeli S; Yetgin S
Turk J Pediatr; 2006; 48(3):248-52. PubMed ID: 17172070
[TBL] [Abstract][Full Text] [Related]
28. Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
Culbert EC; Schfirin BS
Obstet Gynecol; 2006 Sep; 108(3 Pt 2):789-91. PubMed ID: 17018504
[TBL] [Abstract][Full Text] [Related]
29. [New development in bisphosphonate treatment. Treatment with bisphosphonates for cancer-induced bone disease].
Abe M
Clin Calcium; 2009 Jan; 19(1):55-62. PubMed ID: 19122265
[TBL] [Abstract][Full Text] [Related]
30. [The pharmacology of biphosphonates and their use in hypercalcemia].
Adam Z; Vorlícek J; Tomíska M
Vnitr Lek; 1994 Oct; 40(10):667-70. PubMed ID: 7810087
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of hypercalcemia of tumoral origin with two diphosphonates].
Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
Schweiz Med Wochenschr; 1980 Nov; 110(48):1822-4. PubMed ID: 6792698
[TBL] [Abstract][Full Text] [Related]
32. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
33. Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate.
Cagle AP; Waguespack SG; Buckingham BA; Shankar RR; Dimeglio LA
Pediatrics; 2004 Oct; 114(4):1091-5. PubMed ID: 15466114
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of malignancy-associated hypercalcemia].
Endo I; Inoue D
Clin Calcium; 2006 Apr; 16(4):665-69. PubMed ID: 16582519
[TBL] [Abstract][Full Text] [Related]
35. Role of the nurse in preserving patients' independence.
Maxwell C
Eur J Oncol Nurs; 2007; 11 Suppl 2():S38-41. PubMed ID: 17768093
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
37. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Locker GJ; Sevelda U; Zielinski CC; Steger GG
Support Care Cancer; 2004 Sep; 12(9):678-81. PubMed ID: 15160319
[TBL] [Abstract][Full Text] [Related]
38. Hypercalcemia of malignancy: diagnosis and therapy.
Fetchick DA; Mundy GR
Compr Ther; 1986 Aug; 12(8):27-32. PubMed ID: 2943551
[TBL] [Abstract][Full Text] [Related]
39. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
Clines GA; Guise TA
Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
[TBL] [Abstract][Full Text] [Related]
40. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
